z-logo
Premium
B cell activation through CD 40 and IL 4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL
Author(s) -
Ferrer Gerardo,
Bosch Rosa,
Hodgson Kate,
Tejero Rut,
Roué Gael,
Colomer Dolors,
Montserrat Emili,
Moreno Carol
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12645
Subject(s) - b cell activating factor , cd40 , ighv@ , receptor , breakpoint cluster region , chronic lymphocytic leukemia , cancer research , b cell , immunology , biology , medicine , antibody , leukemia , cytotoxic t cell , in vitro , biochemistry
Summary The two tumour necrosis factor family proteins BAFF ( TNFSF 13B) and APRIL ( TNFSF 13) and their receptors [ BAFF ‐R ( TNFRSF 13C), TACI ( TNFRSF 13B), BCMA ( TNFRSF 17)] play a critical role in the survival of normal B cells. The sensitivity of normal B cells to BAFF and APRIL can be modulated by signals regulated by their receptors. This modulation, however, has not been extensively investigated in chronic lymphocytic leukaemia ( CLL ) cells. We evaluated the expression, regulation and signalling of BAFF and APRIL receptors in normal and in CLL cells upon stimulation through CD 40+ IL 4R and BCR . We further analysed the prognostic value of BAFF and APRIL receptors expression in patients with CLL . BCMA expression was significantly higher on CLL cells than on normal B cells. BCR and CD 40+ IL 4R stimulation promoted an increase in TACI and BCMA expression, cell viability and activation in normal B cells. A similar effect was observed in CLL cells after CD 40+ IL 4R but not BCR stimulation. BCMA expression correlated with unmutated IGHV genes, poor‐risk cytogenetics, and short progression‐free survival. These findings further characterize the link between CD 40+ IL 4R regulatory signals, BAFF , APRIL and their receptors and the survival of leukaemic cells and clinical features of CLL .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom